IYIsmail Yaz

Ismail Yaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ismail Yaz has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mucosal Immune Dysregulation: Eosinophilic Gastrointestinal Disorders and Inborn Errors of Immunity

    by Deniz Ilgun Gurel, Elif Soyak Aytekin, Hayriye Hizarcioglu Gulsen, Saliha Esenboga, Emre Ozdamar, Ismail Yaz, Begum Ozbek, Ersin Gumus, Sinan Sari, Arzu Bakirtas, et al.

  • Clinical Heterogeneity of TNFRSF13B Variants: A Monogenic Cause or a Genetic Modifier?

    by Begum Cicek, Deniz Ilgun Gurel, Ismail Yaz, Sevda Tuten Dal, Hacer Neslihan Bildik, Baran Erman, Canberk Ipsir, Elif Soyak Aytekin, Saliha Esenboga, Ilhan Tezcan, et al.

    Transmembrane activator and calcium‐modulator and cyclophilin‐ligand interactor (TACI), encoded by TNFRSF13B, plays a central role in B cell maturation and antibody responses through its interactions with BAFF and APRIL, with variants being linked to common variable immunodeficiency (CVID) and selective IgA deficiency. To characterise the clinical, immunological and genetic spectrum of these individuals, we recruited 30 participants (21 patients and nine family members) and classified patients into Group 1 ( n = 16), carrying only TACI variants and Group 2 ( n = 5), carrying both an IEI‐related variant and an additional TACI variant. With a male/female ratio of 12/9, the median age was 2 years at symptom onset and 14 years at genetic diagnosis. Common clinical manifestations included recurrent infections (90%), autoimmune/inflammatory features (62%) and lymphoproliferation (57%). Twelve distinct TNFRSF13B mutations were identified, predominantly clustering in the cysteine‐rich domain 2 (CRD2), with Cys104Arg being the most frequent (57%) variant. Immunophenotyping revealed decreased switched‐memory and marginal zone B cells, reduced naïve CD4 + T cells and increased effector memory subsets. Notably, clinical and laboratory features overlapped between Groups 1 and 2, as well as between monoallelic and biallelic TNFRSF13B variant carriers. Patients with TNFRSF13B variants display broad phenotypic heterogeneity ranging from asymptomatic carriage to CVID and combined immunodeficiency phenotypes. Given the high polymorphism ratio and incomplete penetrance observed, TACI acts as both a genetic modifier and a monogenic disease‐causing gene in this cohort, suggesting that coexisting genetic variants and exposomal factors likely determine the clinical expression and disease severity.

  • Could we discuss the molecular signature of immune dysregulation?

    by Hacer Neslihan Bildik, Ismail Yaz, Saliha Esenboga, Deniz Cagdas

    Introduction: Immune dysregulation (ID), defined as aberrant immune activation or suppression, may result in autoimmune or inflammatory disorders, lymphoproliferative malignancies, and allergic diseases. Apoptosis, nuclear factor-κB (NFκB), and phosphoinositide 3-kinase (PI3K) pathways are major pathways involved in ID. Objective: This study aimed to assess ID using targeted inflammatory gene-expression profiles in comparison with controls. Methods: We grouped patients according to presenting features: autoimmune lymphoproliferative syndrome (ALPS) (group 1), immune cytopenia (group 2), and EBV-associated lymphoproliferation (group 3). We established real-time quantitative polymerase chain reaction (RT-qPCR) analysis for selected genes (CASP8, CASP10, FAS, FASL, AKT, MAP3K7, MAP3K14, mTOR, NFKB1, NFKB2, NFKBIA, and TRAF3) involved in inflammatory pathways, and calculated gene expression fold changes using the logarithmic Delta-Delta Ct (2^(–delta delta CT)) method. Results: The median age of symptom onset in group 1 (n=10), group 2 (n=12), and group 3 (n=10) was 9.3 (0.5-38.7), 5.7 (0.7-19), 22.5 (0.7-45) years, respectively (p=0.181). The median age at hospital admission was 12 (1.9-38.7), 9.4 (2.3-35), and 34.8 (0.9-54.7) years in groups 1, 2, and 3, respectively (p=0.152). There was a significant difference between patient and control groups (p<0.05), but none among patient groups regarding targeted gene expression (relative quantification values). According to ROC curve analysis, the most discriminative target genes are NFKB2, MAP3K7, AKT, mTOR, NFKB1, and FAS. Conclusion: We propose an ID signature that includes targeted gene expression profiles (NFKB1, NFKB2, MAP3K7, AKT, mTOR, and FAS) and suggest using these specific gene expressions as a biomarker for diagnosis and therapy response in ID.


  • Open Access

    From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

    by Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, et al.

    Background: Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective: To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess diagnostic utility of IFN signature, CXCL10 levels, antiviral activity. Methods: Forty‐six patients with clinical or genetic findings consistent with type I interferonopathies were included. The IFN signature, CXCL9 and IFNG were assessed using RT‐qPCR (n=34 each). Serum CXCL10 and CXCL9 were measured by ELISA (n=37 each). WES was performed for molecular diagnosis (n=46). Antiviral activity was evaluated using rVSV‐GFP (n=5). Results: Two groups were defined: genetically confirmed and undifferentiated interferonopathies. Molecular diagnosis was established in 37/46 (80%) of the patients. IFN signature was evaluable in 34/46 and positive in 31/34 (91%); median IFN score was higher in patients (ps =0.4994, p=0.0026). Both IFN score and CXCL10 showed strong discriminative capacity. Autoantibodies were detected in 67%. Antiviral activity varied across phenotype. Conclusion: Our findings highlight the clinical and molecular diversity of interferonopathies and underscore the possible diagnostic utility of CXCL10 levels. We define a group of patients with consistent clinical features and clear interferon signatures as undifferentiated interferonopathies. Variable antiviral responses indicate differential IFN pathway modulation. These results support the integration of molecular and functional IFN profiling into the diagnostic workup and monitoring of suspected interferonopathies, which may aid in precision medicine. image

  • Overlap of familial Mediterranean fever and APLAID treated with anakinra: a case-based review

    by Gulsen Akoglu, Ismail Yaz, Saliha Esenboga, Sedat Yilmaz, Deniz Dogan Mulazimoglu, Deniz Cagdas

    Autoinflammatory diseases encompass a group of inherited disorders characterized by genetic defects in innate immunity and leading to uncontrolled systemic or organ-specific inflammation. While familial Mediterranean fever is a common example prevalent in Mediterranean regions, autoinflammatory phospholipase C gamma 2 (PLCG2)-associated antibody deficiency and immune dysregulation (APLAID) is extremely rare. We present a 36-year-old male patient with recurrent pustular eruptions who was on colchicine treatment for FMF. Genetic analysis revealed a heterozygous c.2120C > A (Ser707Tyr) mutation in the PLCG2 gene. Daily anakinra 100 mg therapy provided long-term control on skin eruptions. A case-based review following CaBArET guidelines was conducted using Medline/PubMed and Scopus databases and identified 30 cases of APLAID to review the clinical manifestations and treatment approaches of APLAID. No phenotype–genotype association has been established and treatment outcomes of APLAID patients are variable. Our case highlights reconsidering the diagnosis of a patient with persistent and atypical inflammatory manifestations even if he has a diagnosis of an autoinflammatory disorder. Although treatment responses to anakinra reported in the literature are scarce and highly variable, our observations demonstrated that anakinra seems to be a promising agent, especially for recurrent pustular eruptions of APLAID. Key Points • Skin is potentially the most demonstrative and available target of autoinflammatory disorders. • Detailed history, examinations and subsequent WES analysis may provide the correct diagnosis of APLAID, even in a patient who has already an autoinflammatory disorder. • Anakinra may be a promising agent for the treatment of skin eruptions in APLAID patients.

  • Open Access

    A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects

    by Hacer Neslihan Bildik, Saliha Esenboga, Sevil Oskay Halaclı, Betül Karaatmaca, Elif Soyak Aytekin, Nadira Nabiyeva, Ayşegul Akarsu, Melike Ocak, Baran Erman, Cagman Tan, et al.

    Background: Phosphoinositide 3 kinases (PI3K) are lipid kinases expressed in lymphocytes/myeloid cells. PI3K/AKT/mTOR signaling defects present with recurrent infections, autoimmunity, lymphoproliferation, and agammaglobulinemia.Objective: To characterize the PI3K/AKT/mTOR pathway defects and perform pathway analyses to assess novel variant pathogenicity.Methods: We included 12 patients (heterozygous PIK3CD (n = 9) and PIK3R1 (n = 1) (activated PI3K delta syndrome (APDS) with gain‐of‐function mutations) and homozygous PIK3R1 variant (n = 2)), performed clinical/laboratory/genetic evaluation, and flow cytometric PI3K/AKT/mTOR pathway analyses.Results: Median age at onset of complaints was 17.5 months (3 months to 12 years) and at diagnosis was 15.7 years (2.5–37) in APDS. Median diagnostic delay was 12.9 years (1.6–27). Recurrent respiratory tract infections (90%), lymphoproliferation (70%), autoimmune/inflammatory findings (60%), and allergy (40%) were common in APDS. Recurrent viral infections were present in 4/10 and malignancy (non‐Hodgkin lymphoma and testicular yolk sac tumor) was present in 2/10 in APDS. Low CD4+ T cells(5/8) with increased CD4+ effector memory (8/8) and CD4+ TEMRA cells (6/8) were present in the given number of APDS patients. We diagnosed tubulointerstitial nephritis, Langerhans cell histiocytosis, and late‐onset congenital adrenal hyperplasia in APDS. Allergic findings, lymphoproliferation/malignancy, and high IgM were present in the APDS but not in PIK3R1 deficiency. Low IgM/IgG/CD19+ B cell counts were characteristic in patients with PIK3R1 homozygous loss‐of function mutations.Conclusion: Differential diagnosis with combined immunodeficiency and diseases of immune dysregulation make molecular genetic analysis crucial for diagnosing mTOR pathway defects. It is easy to differentiate APDS and homozygous PIK3R1 defects with specific laboratory features. Additionally, mTOR pathway functional analysis is a definitive diagnostic and pathogenicity assessment tool for novel APDS mutations. image


  • Clinical and Osteopetrosis-Like Radiological Findings in Patients with Leukocyte Adhesion Deficiency Type III

    by Ayca Burcu Kahraman, Ismail Yaz, Rahsan Gocmen, Selin Aytac, Ayse Metin, Sara Sebnem Kilic, Ilhan Tezcan, Deniz Cagdas


  • In case of recurrent wheezing and bronchiolitis: Think again, it may be a primary immunodeficiency

    by Begum Ozbek, Deniz Cagdas Ayvaz, Saliha Esenboga, Sevil Oskay Halacli, Elif Soyak Aytekin, Ismail Yaz, Cagman Tan, Ilhan Tezcan

    Background: Wheezing, starting early in life, is a heterogeneous medical condition caused by airway obstruction due to different underlying mechanisms. Primary immunodeficiencies are also among the risk factors that cause wheezing and recurrent bronchiolitis. ADA deficiency is a primary immunodeficiency, also a rare metabolic disease associated with multisystemic clinical findings. Objective: This report will be helpful for adressing the importance of thinking primary immunodeficiency in case of wheezing and recurret bronchiolitis. Methods: The patient was diagnosed by using a targeted next generation sequencing PID panel. Lymphocyte subsets were measured by flow-cytometry. Results: Here we present an infant with ADA deficiency who admitted with wheezing and recurrent bronchiolitis as the first presentation. He was found to have wheezing, relative CD4+ T cell deficiency, and prolonged neutropenia. Conclusion: Primary immunodeficiencies including ADA deficiency should be considered in infants with wheezing, recurrent bronchiolitis, lymphopenia and neutropenia.


  • Open Access

    Clinical and laboratory findings in patients with leukocyte adhesion deficiency type I: A multicenter study in Turkey

    by Ismail Yaz, Begum Ozbek, Hacer Neslihan Bildik, Cagman Tan, Sevil Oskay Halacli, Elif Soyak Aytekin, Saliha Esenboga, Sukru Cekic, Sara Sebnem Kilic, Ozlem Keskin, et al.

    Leukocyte adhesion deficiency type I is a rare primary immunodeficiency disorder characterized by mutations in the ITGB2 gene encoding CD18. We present clinical and immunological features of 15 patients with leukocyte adhesion deficiency type 1 (LAD-1). Targeted next-generation sequencing was performed with either a primary immunodeficiency gene panel comprising 266 genes or a small LAD-panel consisting of five genes for genetic analysis. To measure the expression level of integrins on the leukocyte surface, flow cytometry analysis was performed. The median age of the patients at diagnosis was 3 (1–48) months. Eleven (73%) of the 15 patients had a LAD-1 diagnosis in their first 6 months and 14 (93%) patients had consanguineous parents. Delayed separation of the umbilical cord was present in 80% (n = 12) of the patients in our cohort, whereas omphalitis was observed in 53% (n = 8) of the patients. Leukocytosis with neutrophil predominance was observed in 73% (n = 11) patients. Nine distinct variants in the ITGB2 gene in 13 of the 15 patients with LAD-1 were characterized, two of which (c.305_306delAA and c.779_786dup) are novel homozygous mutations of ITGB2. Four unrelated patients from Syria had a novel c.305_306delAA mutation that might be a founder effect for patients of Syrian origin. Four (27%) patients underwent hematopoietic stem cell transplantation. Two patients died because of HSCT complications and the other two are alive and well. Early differential diagnosis of the patients is critical in the management of the disease and genetic evaluation provides a basis for family studies and genetic counseling.


  • Open Access

    Clinical and Laboratory Findings in Patients with Leukocyte Adhesion Deficiency Type I: A Multicenter Study in Turkey

    by Ismail Yaz, Begum Ozbek, Hacer Neslihan Bildik, Cagman Tan, Sevil Oskay Halacli, Elif Soyak Aytekin, Saliha Esenboga, Sukru Cekic, Sebnem Sara Kilic, Ozlem Keskin, et al.

    Leukocyte adhesion deficiency type I is rare primary immunodeficiency disorder characterized by mutations in the ITGB2 gene encoding CD18. We present clinical and immunological features of 15 patients with leukocyte adhesion deficiency type I (LAD-I). Targeted next-generation sequencing was performed with either a primary immunodeficiency gene panel comprising 266 genes or a small LAD-panel consisting of five genes for genetic analysis. To measure the expression level of integrins on the leukocyte surface, flow cytometry analysis was performed. The median age of the patients at diagnosis was 3 (1-48) months. Eleven (73%) of the 15 patients had LAD-I diagnosis in their first 6 months, and fourteen (93%) patients had consanguineous parents. Delayed separation of the umbilical cord was present in 80% (n=12) of the patients in our cohort, whereas omphalitis was observed in 53% (n=8) of the patients. Leukocytosis with neutrophil predominance was observed in 73% (n=11) patients. Nine distinct variants in the ITGB2 gene in 13 of the 15 patients with LAD-I were characterized, of which two (c.305_306delAA and c.779_786dup) are novel homozygous mutations of ITGB2 . Four unrelated patients from Syria had a novel c.305_306delAA mutation that might be a founder effect for patients of Syrian origin. Four (27%) patients underwent HSCT. Two of them died because of HSCT complications, and the other two are alive and well. Early differential diagnosis of the patients is critical in the management of the disease and genetic evaluation provides a basis for family studies and genetic counseling.